Repurposing Atovaquone as a Tumor Hypoxia Modifier: A Window of Opportunity Study in Patients with Resectable Non-small Cell Lung Cancer

被引：0
|
作者：
Skwarski, M. [1 ]
McGowan, D. R. [1 ]
Belcher, E. [2 ]
Di Chiara, F. [2 ]
Stavroulias, D. [2 ]
Prevo, R. [1 ]
Macklin, P. S. [1 ]
Chauhan, J. [1 ]
O'Reilly, D. [1 ]
Green, M. [1 ]
Ferencz, P. [1 ]
Rodriguez-Berriguete, G. [1 ]
Flight, H. [1 ]
Qi, C. [1 ]
Holmes, J. [1 ]
Buffa, F. [1 ]
McCole, M. [2 ]
Bulte, D. [1 ]
Macpherson, R. [2 ]
Higgins, G. S. [1 ]
机构：
[1] Univ Oxford, Oxford, England
[2] Oxford Univ Hosp NHS Trust, Oxford, England
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 108卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1120
引用
收藏
页码：S173 / S173
页数：1
相关论文
共 50 条
  • [1] A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
    Owonikoko, Taofeek K.
    Force, Seth
    Sica, Gabriel
    Bechara, Rabih
    Harvey, R. D.
    Sun, Shi-Yong
    Saba, Nabil
    Rogerio, Jaqueline
    Gal, Anthony
    Kono, Scott
    Miller, Daniel
    Ramalingam, Suresh
    Khuri, Fadlo R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S967 - S968
  • [2] A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC)
    Dragnev, K. H.
    Ma, T.
    Galimberti, F.
    Erkmen, C. P.
    Memoli, V.
    Nugent, W.
    Rigas, J. R.
    Johnstone, D.
    Frandsen, A.
    Simeone, S.
    Czum, J.
    Li, H.
    DiRenzo, J.
    Freemantle, S.
    Dmitrovsky, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).
    Owonikoko, Taofeek Kunle
    Miller, Daniel L.
    Force, Seth
    Sica, Gabriel
    Kono, Scott
    Behera, Madhusmita
    Mendel, Jennifer
    Chen, Zhengjia
    Pickens, Allan
    Fu, Robert W.
    Auffermann, William F.
    Rogerio, Jaqueline
    Torres, William E.
    Fu, Haian
    Hohneker, John
    Sun, Shi-Yong
    Gal, Anthony A.
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    CANCER RESEARCH, 2013, 73 (08)
  • [4] Evaluation of neoadjuvant "window of opportunity" trials with targeted therapy in patients with surgically resectable non-small cell lung cancer.
    Stiles, B. M.
    Mirza, F.
    Chiu, Y.
    Port, J. L.
    Lee, P. C.
    Paul, S.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Serum tumor markers in resectable and non-resectable non-small cell lung cancer
    Nisman, B
    Heching, N
    Barak, V
    JOURNAL OF TUMOR MARKER ONCOLOGY, 2000, 15 (03): : 195 - 207
  • [6] Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study
    Tan, A.
    Chua, K. P.
    Takano, A.
    Alvarez, J.
    Ong, B. H.
    Koh, T.
    Aung, Z. W.
    Jain, A.
    Lai, G.
    Tan, W. L.
    Ang, M. K.
    Ng, Q. S.
    Kanesvaran, R.
    Rajasekaran, T.
    Iyer, N. G.
    Lim, W. T.
    Zhai, W.
    Toh, C. K.
    Skanderup, A.
    Tan, E. H.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S609 - S610
  • [7] Neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
    Broderick, Stephen R.
    Bott, Matthew J.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 158 (05): : 1471 - 1474
  • [8] Management of Patients With Resectable and Metastatic Non-Small Cell Lung Cancer
    Yanagawa, Jane
    Riely, Gregory J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (5.5):
  • [9] Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
    Laura Gutierrez-Sainz
    Patricia Cruz-Castellanos
    Oliver Higuera
    Javier de Castro-Carpeño
    Current Treatment Options in Oncology, 2021, 22
  • [10] Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
    Gutierrez-Sainz, Laura
    Cruz-Castellanos, Patricia
    Higuera, Oliver
    De Castro-Carpeno, Javier
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (10)
12345